Melbourne based dorsaVi Limited's (ASX:DVL) wearable movement sensors have shown a significant and sustained improvement in pain and functional ability when worn by back pain patients in a clinical trial, according to new data.
This is the first clinical trial of its kind to investigate the effect that technology can have on the rehabilitation of low back pain.
dorsaVi’s ViMove is a wearable sensor system that turns human movement into actionable, easily interpreted data.
The clinical trial investigated whether changing patterns of lumbo-pelvic movement and/or posture using motion sensor biofeedback, provided by ViMove, in people with LBP would lead to reduced pain and activity limitation when compared with guidelines-based medical treatment or physiotherapy.
Participants treated with the dorsaVi sensors with biofeedback showed a 35% to 47% improvement at 12 months, which were all above the threshold for clinically important difference (>30 % of baseline scores)
The study involved a 12 month, multicentre, cluster randomised, placebo controlled clinical trial sponsored by dorsaVi and the Victorian Government.
The trial involved 112 patients – 58 in the interventional group (which received ViMove) and 54 in the control group.
Most non-surgical treatments for non-specific LBP showed only small to moderate effects with one treatment showing little superiority over the other.
dorsaVi’s sensors provide real-time feedback about high risk positions for patients with back pain and also encourages positive movement patterns.
This data informs decisions by the treating healthcare professional to modify their patients’ daily movements.
This reduces their risk of another episode and reducing recovery time. ViMove is approved for use in Australia and Europe and cleared by the FDA under 510(k) for the United States.
This article was originally published on Proactive Investors Australia